Early in-hospital initiation and optimization of comprehensive disease-modifying pharmacotherapy in patients with heart failure with reduced ejection fraction: a time for the paradigm shift (CROSBI ID 305310)
Prilog u časopisu | kratko priopćenje | međunarodna recenzija
Podaci o odgovornosti
Borovac, Josip Anđelo
engleski
Early in-hospital initiation and optimization of comprehensive disease-modifying pharmacotherapy in patients with heart failure with reduced ejection fraction: a time for the paradigm shift
This paper synthesizes and organizes the latest relevant data regarding the novel pharmacotherapies for the clinical syndrome of heart failure with reduced ejection fraction (HFrEF). The main goal of the article is to emphasize the importance of the introduction of all foundational drugs in patients with HFrEF during hospitalization or at least before hospital discharge. Furthermore, based on the available data, this manuscript provides a putative scheme/pathway for rapid initiation and subsequent up-titration of these crucial disease-modifying therapies that have demonstrated a profound impact on mortality and morbidity in this population. This is a novel concept that replaces traditional, slow, and sequential initiation of life-saving therapies.
beta-blockers ; heart failure with reduced ejection fraction ; HFrEF ; mineralocorticoid antagonists ; MRA ; sacubitril/valsartan ; ARNI ; quadruple therapy ; SGLT2 ; sodium glucose co-transporter 2 ; outcomes ; morbidity ; mortality ; uptitration ; acute decompensated heart failure ; evidence-based treatment ; RCT
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
20 (2)
2022.
91-94
objavljeno
1477-9072
1744-8344
10.1080/14779072.2022.2039626
Povezanost rada
Kliničke medicinske znanosti